24 April 2014
Versant Ventures has led a $25m Series A financing round for biopharmaceutical business CRISPR Therapeutics, which is currently working on a breakthrough gene editing technology.
Read full story
The outlook for infrastructure private equity and venture industry - from the latest AltAssets' LP-GP Forum
David Valger, founder of DVO Real Estate, believes he has found a gap in the market for investing in Class B US real estate – a segment he says is always in demand
AltAssets is registered as a trademark of Investor Networks Limited (06695690).Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJContent is © AltAssets 2000-2016